Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAAOI-1 in clozapine-resistant schizophrenia
NCT01390376Phase 2Completed
- Sponsor
- China Medical University Hospital
- Start
- Sep 2010
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DAAOI-1 in schizophrenia, sponsored by China Medical University Hospital. Primary endpoint: Positive and Negative Syndrome Scale at 6 weeks. Started Sep 2010; status: completed.
02
Drugs
DAAOI-1
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01390376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01390376.